QL1706
- Generic Name
- QL1706
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
QL1706 is an investigational bifunctional antibody that combines the activity of both PD-1 and CTLA-4 antibodies.
- Associated Conditions
- -
- Associated Therapies
- -
QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT06750861
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Chaoyang District, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath